Apellis Pharmaceuticals Inc
APLS
Market Cap$2.56B
Close$
$-40.45
327.1% downside
Current Fair Value
327.1% downsideOvervalued by 327.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.56 Billion |
|---|---|
| Enterprise Value | $2.61 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.6 |
| Beta | 0.84 |
| Outstanding Shares | 123,904,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -12.74 |
|---|---|
| PEG | 21.57 |
| Price to Sales | 3.56 |
| Price to Book Ratio | 17.81 |
| Enterprise Value to Revenue | 3.88 |
| Enterprise Value to EBIT | -9.88 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Apellis Pharmaceuticals Inc
CEO: Cedric Francois